Paradigm Biopharmaceuticals Limited Stock Performance
| PBIGF Stock | USD 0.23 0.01 4.55% |
On a scale of 0 to 100, Paradigm Biopharmaceutica holds a performance score of 7. The company holds a Beta of 1.91, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Paradigm Biopharmaceutica will likely underperform. Please check Paradigm Biopharmaceutica's maximum drawdown, skewness, price action indicator, as well as the relationship between the downside variance and rate of daily change , to make a quick decision on whether Paradigm Biopharmaceutica's historical price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Paradigm Biopharmaceuticals Limited are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Paradigm Biopharmaceutica reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Paradigm |
Paradigm Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 17.00 in Paradigm Biopharmaceuticals Limited on September 15, 2025 and sell it today you would earn a total of 6.00 from holding Paradigm Biopharmaceuticals Limited or generate 35.29% return on investment over 90 days. Paradigm Biopharmaceuticals Limited is currently producing 0.8419% returns and takes up 9.1743% volatility of returns over 90 trading days. Put another way, 82% of traded pink sheets are less volatile than Paradigm, and 84% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Paradigm Biopharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Paradigm Biopharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Paradigm Biopharmaceuticals Limited, and traders can use it to determine the average amount a Paradigm Biopharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0918
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PBIGF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Paradigm Biopharmaceutica is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Paradigm Biopharmaceutica by adding it to a well-diversified portfolio.
Paradigm Biopharmaceutica Fundamentals Growth
Paradigm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Paradigm Biopharmaceutica, and Paradigm Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Paradigm Pink Sheet performance.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.44 | |||
| Operating Margin | (604.99) % | |||
| Current Valuation | 217 M | |||
| Shares Outstanding | 282.24 M | |||
| Price To Book | 8.76 X | |||
| Price To Sales | 3,287 X | |||
| Revenue | 79.22 K | |||
| EBITDA | (39.16 M) | |||
| Cash And Equivalents | 39.72 M | |||
| Cash Per Share | 0.17 X | |||
| Total Debt | 616.67 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.18 X | |||
| Cash Flow From Operations | (32.21 M) | |||
| Earnings Per Share | (0.14) X | |||
| Total Asset | 50.69 M | |||
About Paradigm Biopharmaceutica Performance
By analyzing Paradigm Biopharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Paradigm Biopharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Paradigm Biopharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Paradigm Biopharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. The company was incorporated in 2014 and is based in Melbourne, Australia. Paradigm Biopharmaceutica operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Paradigm Biopharmaceutica performance evaluation
Checking the ongoing alerts about Paradigm Biopharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Paradigm Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Paradigm Biopharmaceutica is way too risky over 90 days horizon | |
| Paradigm Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Paradigm Biopharmaceutica appears to be risky and price may revert if volatility continues | |
| Paradigm Biopharmaceutica has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 79.22 K. Net Loss for the year was (39.25 M) with loss before overhead, payroll, taxes, and interest of (64.53 K). | |
| Paradigm Biopharmaceuticals Limited has accumulated about 39.72 M in cash with (32.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Paradigm Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Paradigm Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Paradigm Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Paradigm Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Paradigm Biopharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Paradigm Biopharmaceutica's pink sheet. These opinions can provide insight into Paradigm Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Paradigm Pink Sheet analysis
When running Paradigm Biopharmaceutica's price analysis, check to measure Paradigm Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Paradigm Biopharmaceutica is operating at the current time. Most of Paradigm Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Paradigm Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Paradigm Biopharmaceutica's price. Additionally, you may evaluate how the addition of Paradigm Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |